CD274 and adenosquamous carcinoma: In the detailed subgroup analysis of NSCLC variants and their PD-L1 expression status performed by Pawelczyk and colleagues, the expression levels of PD-L1 in adenosquamous carcinoma were documented on the lower end of the spectrum, with 78.1% of cases displaying low levels (<1%) and only 3.1% reaching the threshold of ≥50% to qualify for high expression [42].